What analyst predict for EyePoint Pharmaceuticals NASDAQ:EYPT?

0
916

What analyst predict for EyePoint Pharmaceuticals NASDAQ:EYPT?

EyePoint Pharmaceuticals NASDAQ:EYPT headquartered in Watertown, Massachusetts, United States is reporting their earnings on 09/12/2018 before the bell. Street forecast for the quarter ending March 2018 is $-0.09.

According to stock market daily analyst this is Lower then same time previous year. EyePoint Pharmaceuticals, reported EPS for the same quarter last year was $-0.16.

()
()

Chart

About EyePoint Pharmaceuticals NASDAQ:EYPT

EyePoint Pharmaceuticals, Inc. (formerly pSivida Corp.) is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders. The Company has developed 3 FDA-approved sustained-release treatments in ophthalmology. In addition, DEXYCU (dexamethasone intraocular suspension) 9% was approved by U.S. Food and Drug Administration (FDA) on February 9, 2018. ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg, a micro-insert licensed to Alimera Sciences, is currently sold directly in the U.S. and several EU countries. Retisert® (fluocinolone acetonide intravitreal implant) 0.59 mg, an implant, is licensed to and sold by Bausch & Lomb. The New Drug Application (NDA) for our lead product candidate, DurasertTM (fluocinolone acetonide intravitreal implant) 0.18 mg micro-insert has been accepted for filing by the U.S. Food and Drug Administration (FDA) and is currently under standard review with a Prescription Drug User Fee Act (PDUFA) date of November 5, 2018. The Company’s pre-clinical development program is focused on using its core Durasert Technology platform to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis and other diseases.

EYPT
Name
Change
% Change
Market Cap
% Change from 52 Week Low
% Change from 52 Week High
Shares Outstanding
Volume
Dividend Rate

What analyst predict for Applied Genetic Technologies Corporation NASDAQ:AGTC?